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Abstract The pharmacokinetics of torasemide, a new 
loop diuretic, as well as its active metabolites M1 and 
M3, and its inactive main metabolite, M5, were studied 
in 12 patients with end-stage renal f ilure during single 
i.v. (n = 6) or single oral (n = 6) dosing of 200 mg torase- 
mide, and during chronic oral treatment for 9 days 
(n : 12). 
The elimination half-life (t~/2) of torasemide was un- 
changed in renal failure, whereas tl/2 of the torasemide 
metabolites M1, M3, and M5 were markedly prolong- 
ed. However  tl/2 as well as the area under the plasma 
level time curve of torasemide and its metabolites were 
unchanged uring chronic compared to acute adminis- 
tration. 
The results of this study suggest hat despite the in- 
creased half-life of torasemide metabolites M1, M3 and 
M5 in end-stage renal failure patients, no accumulation 
of the parent drug torasemide and its metabolites dur- 
ing chronic dosing is demonstrable. 
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Torasemide is a new loop diuretic with a prolonged half- 
life (in comparison to furosemide) and proven efficacy 
for treatment of patients with renal failure, hyperten- 
sion, and heart failure [I, 2]. Torasemide is 1-isopropyl- 
3-{[4- (3-methyl-phenylamino)pyridine]-3-sulfonyl}urea, 
and in torasemide metabolite M1, H is substituted by 
OH at the methyl group of the phenyl ring. Further oxi- 
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dization of metabolite M1 yields the respective car- 
boxylic acid (M5), whereas metabolite M3 is formed by 
ring hydroxylation at position 4 of the phenol ring from 
torasemide. The pharmacodynamics of torasemide 
have been studied extensively in patients with renal fail- 
ure, demonstrating a prolonged, marked diuretic effect 
in a dose-dependent manner in the dose range of 100- 
200 mg [3-8]. Some authors have observed less kaliur- 
esis with torasemide than furosemide [5, 6]. 
However, the pharmacokinetics of torasemide and 
its metabolites have been studied in patients with chron- 
ic renal failure only after a single i. v. dose [3, 4]. In these 
studies the terminal half-life of elimination of the active 
metabolite, M3, and the inactive main metabolite, M5, 
was markedly prolonged, whereas the terminal half-life 
of elimination of torasemide was unchanged [3, 4]. The 
aim of the present study therefore was to study the phar- 
macokinetics of torasemide and its active metabolites 
M1, M3, and, its inactive main metabolite, M5, after sin- 
gle as well as after multiple oral and i.v. dosing. 
Patients and methods 
Twelve patients with end-stage r nal disease on haemodialysis 
treatment and with residual urine volume < 1000 ml were studied 
during single and repeated dosing of 200 mg torasemide. The cause 
of renal failure was diabetes (n = 4), pyelonephritis (n = 1), glomer- 
ulonephritis (n = 1), polycystic kidneys (n = 1), radiation ephritis 
(n = 1), multiple myeloma (n = 1), and unknown (n - 3). The study 
protocol was approved by the local ethical committee, and all pa- 
tients gave their informed, written consent. Pharmacokinetic 
studies were performed at day 1 after oral (n = 6, group A) or i.v. 
(n = 6, Group B) administration of 200 mg torasemide and at day 
11 after oral (n = 12) administration of 200 mg torasemide from 
day 3 to day 11. Patients of group A were comparable tothose of 
group B with regard to mean age (61 vs 62 years), mean weight (65 
vs 59 kg), mean height (171 vs 174 cm) and sex (4 vs 3 men). Torase- 
mide administration was at 8.00 a.m. each day irrespective of the 
dialysis schedule; however days 1 and 11 were on an interdialytic 
day. Haemodialysis was as a rule performed 3 times a week with a 
duration of 4 h using a polysulfone m mbrane and dialysate and 
blood flows of 500 ml/min and 200 ml/min respectively. Concomi- 
tant medications in our patients consisted of atenolol, betaxolol, bi- 
158 
Table 1 Pharmacokinetic parameters oftorasemide and its metabolites M3 and M5. Median (range) values for AUC, Cma ×, tmax, and tl/2 
are given for group A (single oral dose), group B (single i.v. dose), group C (group A during steady-state oral dosing), and group D 
(group B during steady-state oral dosing) 
A B C D 
Torasemide (n = 6) 
AUC 63.7 118.5 57.0 87.1 
[ug-h. m1-1] (45.0-156.6) (47.9-484.1) (24.2-190.0) (49.2-442.2) 
Cm~ X 12.9 29.0 14.1 24.0 
[ug" ml 1] (7.1-32.7) (20.2-119.3) (8.4-25.4) (13.1-28.2) 
t .... 1.0 0.6 1.2 1.0 
[hi (0.5-8.0) (0.5-1.0) (1.0-3.0) (0.5-1.0) 
tl/2 3.3 4.6 2.7 5.4 
[h] (2.0-11.2) (2.3-19.9) (1.7-12.0) (2.4-16.1) 
Metabolite M3 (n = 6 a) 
AUC 30.6 30.9 13.0 31.2 
lug-h, m1-1] (25.8-84.7) (14.7-795.0) (8.2-30.9) (12.5-162.0) 
Cma × 0.8 0.5 0.8 1.8 
[ug/m1-1] (0.2-0.9) (0.4-13.6) (0.5-1.8) (0.8-7.4) 
trnax 8.0 16.8 7.9 5.5 
[h] (4.0-10.0) (2.8-33.5) (2.3-10.0) (2.0-10.0) 
tl/2 27.9 29.6 18.5 26.8 
[h] (25.5-86.1) (18.4-42.2) (9.8-53.8) (13.9-46.8) 
Metabolite M5 (n = 6) 
AUC 104.5 97.9 49.2 124.1 
[ug. h-ml ~] (65.6-328.7) (71.9-514.0) (18.0-395.1) (27.7-184.1) 
Cma x 6.2 5.7 4.6 10.1 
[ug. m1-1] (4.2-18.2) (3.7-8.0) (3.1-21.3) (3.1-11.8) 
tma x 6.0 5.8 5.0 5.5 
[h] (4.0-24.0) (2.8-30.0) (3.0-10.0) (2.0-10.0) 
tl/2 9.9 9.2 12.2 13.5 
[h] (5.2-20.9) (5.7-37.5) (5.1-28.2) (5.9-36.5) 
a Except A (n = 5) 
soprolol, metoprolol, clonidine, nifedipine, nitrendipine, diltiazem, 
isradipine, dihydralazine, prazosin, urapidil, captopril, isosorbide 
dinitrate, isosorbide mononitrate, molsidomine, digitoxin, calci- 
triol, calcium carbonate, calcium acetate, erythropoetin, predniso- 
lone, cyclosporin A, allopurinol, insulin, ranitidine, omeprazole, ci-
zaprid, thyroxine, aspirin and antacids. Plasma levels of torasemide 
and torasemide metabolites M1, M3, and M5 were measured before 
and 0.5,1, 2, 3, 4, 6, 8, 10, 24, 30, 34, 48 h after dosing. Urinary excre- 
tion of torasemide and its metabolites was measured 0-6, 6-12, 12- 
24, and 24-48 h after dosing. Concentrations of plasma nd urinary 
torasemide and torasemide metabolites M1, M3, and M5 were mea- 
sured by means of high-performance liquid chromatography [9]. 
Non-compartmental kinetic analysis was performed. Calculated 
pharmacokinetic parameters were maximum plasma concentra- 
tion (Crnax), time to peak concentration (tmax) , terminal elimination 
half-life tl/2, and area under the plasma level-time curve (AUC). 
Data are given as median (range) and statistical evaluation was by 
means of the two-sided Wilcoxon matched-pair signed rank test. 
Results 
The Cm~x, tmax, tl/a, and AUC values of torasemide, me- 
tabolite M3, and metabol i te M5 are given in Table 1. 
These pharmacokinet ic  parameters,  though showing a 
high inter-individual variability, were not significantly 
different between acute and chronic dosing. Plasma 
levels of torasemide metabol i te M1 were also not signif- 
icantly different between acute and chronic dosing 
(Fig. 1). AUCs  of metabol i te M1 were in the range of 
4.5-430 ugxh • m1-1, Cma x of metabol i te M1 ranged from 
0.4-10.6 ug.  m1-1, and tma x ranged from0.5-47.8 h; tl/2 
could not be determined for this metabol ite.  
Since the urine volumes were low and the excret ion of 
torasemide and its metabol ites was slight, data are given 
for the t ime per iod 0-48 h during chronic dosing only 
(amounts excreted in urine as a percentage of the ad- 
ministered dose). 0.35 % (0.02-1.31) or 0.58 % (0.03- 
0.96) torasemide, 0.72 % (0.03-3.99) or 0.13 % (0.08- 
1.38) metabol i te M1, 0.62% (0.00-2.35) or 1.04% 
(0.04-1.15) metabol i te M3, and 2.98 % (0.10-64.63) or 
5.35 % (0.34-19.6) metabol i te M5 for patient groups C 
and D (as def ined in Table 1), respectively, were excret- 
ed during the 48 h after dosing. The ratios tl/2 (steady 
state)/tl/2 (single dose) and AUC(s teady  state) /AUC 
(single dose) calculated for each individual patient were 
about 1 for torasemide as well as for torasemide meta- 
bolites M1, M3, and M5. These data (not shown in de- 
tail) did not support accumulat ion of torasemide or its 
metabol ites M1, M3, and M5 during chronic dosing. 
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Fill, 1 Serum concentrations of torasemide metabol ite M]  in group 
A (single oral dose; open squares), group B (single i.v. dose; stars), 
group C (= group A during steady-state oral dosing; hexagons), 
and group D (= group B during steady-state oral dosing; dia- 
monds) 
Discussion 
T1/2 for torasemide, metabolite MI, metabolite M3, and 
metabolite M5 in patients with normal kidney function 
were 2-4 h, 1.3, not determined, and 2-4, respectively 
[3, 10-14]. Torasemide tl/2 and AUC were unchanged 
during chronic dosing in patients with normal renal fun- 
tion, however no published ata are available with re- 
gard to torasemide metabolites during chronic dosing 
[13, 14]. Administration of a single i.v. dose of 20 mg of 
torasemide in patients with chronic renal failure (crea- 
tinine clearance < 48 ml- rain- 0 was associated with an 
unchanged tl/2 of torasemide, however tm of metabo- 
lite M5 was prolonged to 7.4 h [3]. Kult et al. found h/2 
to be prolonged 3-4-fold in patients with chronic renal 
failure (creatinine clearance < 30 ml • min -t) for meta- 
bolite M5 (6.3 or 7.3 h) and metabolite M3 (21.1 or 
19.5 h) after a single i.v. dose of 100 or 200 mg torase- 
mide [4]. However, no pharmacokinetic data in pa- 
tients with renal failure were available in the literature 
with regard to torasemide and its metabolites during 
chronic dosing. These data are provided by the present 
study demonstrating that t~/2 for torasemide is about 3- 
5 h, t~/2 for the metabolite M3 is about 19-26 h, and h/2 
for metabolite M5 is about 12-13 h during chronic dos- 
ing (Table 1); tl/2 for metabolite M1 could not be deter- 
mined, but appears to be > 24 h. Most importantly tl/~ 
as well as AUC for torasemide and its metabolites M1, 
M3, M5 were essentially the same during chronic or 
acute dosing. Ratios between h/2 or AUC during single 
dose and tl/2 or AUC during chronic dosing were about 
i for torasemide and its metabolites, thus providing evi- 
dence against significant accumulation of the parent 
drug or its main metabolites during chronic dosing. The 
rather high inter-individual differences of pharmacoki- 
netic parameters in the present study are most likely re- 
lated to the major hepatic route of elimination of tora- 
semide, whereas kidney function was very similar in all 
patients. 
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Urinary excretion of torasemide and its metabolites 
was low in the present study, being in the range of 
0.5 % of the administered dose during 48 h for torase- 
mide and torasemide metabolite M1, 0.8 % for metabo- 
lite M3, and 4 % for torasemide metabolite M5. In con- 
trast urinary excretion of torasemide and its metabo- 
lites M1, M3 and M5 is 8-25 %, 11-18 %, 2-3 % and 
34-55 %, respectively in patients with normal kidney 
function [10, 12]. Since metabolite M1 has about 1/10 
of the diuretic effect of torasemide and metabolite M3 
has about the same diuretic effect as torasemide [2], 
M1 and M3 are thought to cause at least the same diure- 
tic effect as the parent drug, in contrast to healthy con- 
trols, where torasemide causes about 80 % of the di- 
uresis [12]. 
Judging from the results of the present study and 
from pharmacodynamic studies in patients with severe, 
chronic renal failure 100-200 mg torasemide per day 
given as a single dose seems to be appropriate to induce 
sufficient diuresis and natriuresis [3-8]. 
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